F

ile this under “three strikes and you’re out!”

Twice last fall, the House Committee on Oversight and Government Reform asked Mylan Pharmaceuticals to submit documents about EpiPen pricing, but to date, the company has provided precious few. So last Friday, the committee warned Mylan attorneys that, if the company does not comply, a subpoena may be issued for Mylan execs to testify and produce the documents.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • gag me why are they allowed to exclude the government settlement from their bonus calculation? This is nothing more than a catch up of a business expense or adjustment downward to revenue that should have taken place years ago.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy